To examine the role of different T H effector subsets in melanoma immunity (Fig. 1) , Purwar et al. 3 adoptively transferred in vitro-polarized T H 1, T H 2, T H 9 and T H 17 cells specific for ovalbumin peptide-expressing B16 melanoma into syngeneic immunocompetent mice. Consistently with previously published studies, T H 17 cells mediated potent antitumor immunity [4] [5] [6] [7] [8] [9] . The effects of T H 9 cells were superior to the other effector T cells in this tumor protection model 3 although it remains unclear from this study what role, if any, T H 9 cells have in the treatment of established vascularized tumors. In support of a protective role of IL-9, T H 9 cells or both in tumor immunity, the authors showed that melanoma growth was accelerated in IL-9 receptor-deficient mice compared to heterozygotes for the IL-9 receptor. Furthermore, recombinant IL-9 treatment impaired tumor growth in vaccine and nonvaccine settings. Therefore, IL-9 and/or T H 9 cells inhibit tumor growth, at least in the setting of tumor implantation.
To gain mechanistic insights into how IL-9-producing T cells might inhibit the implantation of experimentally transplanted melanoma, the authors studied T H 9 cells in vitro, finding that T H 9 cells were capable of direct tumor lysis, which was granzyme B dependent 3 . Furthermore, IL-9 administration reduced tumor growth in Rag1-deficient mice, which lack B and T cells, but had no effects on tumor growth in mast cell-deficient mice. These data suggest that tumor growth inhibition mediated by IL-9 depends on the presence of mast cells but not T or B cells. However, the relative impact of mast cells and direct cytotoxicity, or a possible involvement of natural killer cells, in mediating Given the myriad and mutable nature of the challenges they face, it seems easy to imagine why T cells would evolve to acquire a diversity of epigenetic states. T helper (T H ) cells need to be both specific and plastic, but ascertaining the qualities of these states and their precise roles in immune homeostasis is an enormous challenge for modern-day immunobiologists. Production of IL-9 by T H 2-like cells has been known for some time, but the possibility that this cytokine is produced by a distinct T H cell subset-dubbed T H 9 cells-has gained substantial currency in recent years 1 (Fig. 1 ). The role of T H 9 cells in tumor immunity had not been previously investigated in mice or humans, but Purwar et al. 3 inadvertently tackled this problem. While attempting to examine the role of retinoidrelated orphan receptor-γ (ROR-γ), a key transcription factor in the development of the T H 17 cell lineage, in antitumor immunity, the authors found increased IL-9 expression in ROR-γ-deficient T cells. Moreover, mice lacking ROR-γ (Rorc -/-mice) showed reduced tumor growth after subcutaneous injection of melanoma cells compared with Rorc +/+ mice. Hypothesizing that T H 9 and IL-9 played a part in the protective antitumor immunity they observed in the Rorc -/-mice, the authors employed several complementary approaches to test this possibility 3 . They found that administration of a monoclonal neutralizing antibody (mAb) against IL-9 promoted melanoma growth in ROR-γ−deficient mice, IL-23 receptor-deficient mice and wild-type mice.
Nine lives for T H 9s?
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There is currently much interest in dissecting the mechanisms of tumor immunity. A new study shows that a subset of CD4 + T cells that produce the cytokine interleukin-9 (IL-9) mediate inhibition of melanoma growth in mice and that analogous IL-9-producing T cells are present in human skin (pages 1248-1253). Could such cells be manipulated to develop new therapeutic strategies for melanoma? the antitumor effects of IL-9 still remain to be addressed in future studies (Fig. 1) . In correlative studies, the authors identified T H 9 cells in healthy skin in humans as well as in tumor tissues from individuals with melanoma 3 . They also found that T cells from metastatic melanoma produced less IL-9 than that extracted from healthy donors. These early data may stimulate additional work designed to assess a role for T H 9 cells in tumor progression.
Whether there is a causal relationship between ROR-γ deficiency and IL-9 production and T H 9 development remains unexplored. However, given that the transcription factor PU.1 is required for the development of T H 9 cells 10 , it may be interesting to investigate whether ROR-γ deficiency biochemically and functionally affects transcription events downstream of PU.1.
Many questions remain to be answered. It is known that the development of both T H 9 and T H 17 cells may be heavily influenced by the transforming growth factor-β (TGF-β) signaling pathway, but to what extent are T H 9 molecular and functional programming similar to or different from the unique features of T H 17 cells? T H 17 cells can induce potent tumor immunity, and this may be due to the polyfunctionality and plasticity of these cells 7, 8 . Perhaps more importantly, T H 17 cells have the elusive qualities of 'stemness' and longevity 8, 9 . The hypoxia-inducible factor-1α, Notch and Bcl-2 signaling pathways are important for maintaining the T H 17 cell pool 8, 11, 12 , but to what extent do T H 9 cells possess these evolutionarily conserved 'stem cell-like' pathways?
In human epithelial cancers, T H 17 cells constitute a small population compared with other effector T cells 5, 11 . Intratumoral T H 17 number and/or IL-17 abundance correlate with improved survival in multiple human cancers 4 . High amounts of TGF-β, IL-6 and IL-1, which should promote T H 17 cell development, have been detected in the tumor microenvironment 13 . However, T H 17 cells are tightly regulated and suppressed by regulatory T cells in the tumor microenvironment 4, 7, 14 . Given that Purwar et al. 3 observed that the numbers of T H 9 cells were lower in advanced melanoma, similar to what has been observed for T H 17 cells, are T H 9 cells also inhibited by regulatory T cells? In addition to melanoma, are T H 9 cells capable of invading the microenvironments of other human cancers?
Adoptive T cell therapy can induce tumor regression and result in objective clinical responses in patients with cancer 15, 16 . The work of Purwar et al. 3 may imply that IL-9 and T H 9 cells have a role in immune-based anticancer therapy, but the uses of T H 9 cells in tumor treatment remain unresolved in the present study, where treatment of tumors is performed at the time of their implantation. Future work will be required to determine whether T H 9 cells have the 'staying power' to eradicate established tumors. As we approach a new set of potent new T cell-based immunotherapies, translational immunologists will need to ascertain if T H 9 cells have the qualities to eradicate swiftly growing tumor cells in an immunosuppressive and hypoxic tumor microenvironment, qualities that are not assessed by 'day 0' treatment models. Could T H 9 cells have the feline qualities of 'nine lives'? researchers to the discrete and poorly appreciated populations of mesenchymal cells that are wrapped around capillaries 3 . These cells have been variously called perivascular cells, mural cells, pericytes or pericyte-like cells, but relatively little is known about their normal functions. Moreover, substantial controversy persists around their name, as the cells have been defined by their morphology or appearance under electron microscopy rather than by cell function, ontogeny or transcription factor activation 3, 4 .
Dulauroy et al. 2 used elegant genetic studies in mice to map the fate of neural crest cell-derived embryonic mesenchyme, Fibrosis has emerged from something pathologists comment on in passing to a central but incompletely understood process of disease. Fibrosis is widespread in many common diseases with limited treatment options, including cancer, cardiovascular diseases, chronic lung and kidney diseases, liver cirrhosis, inflammatory bowel diseases, muscular atrophy and skin diseases such as scleroderma 1 .
Moreover, fibrosis is now recognized as a process of aging in all organs. There are currently few therapies to treat fibrosis, but at the flagship scientific meeting on fibrosis recently hosted by Keystone Symposia, representatives from 65 pharmaceutical and biotechnology companies committed with renewed gusto to identify therapies to treat this disease process and to bring those therapies to market.
One major problem that has confounded the field(s) has been the lack of understanding of the biological processes involved in fibrosis. However, recent studies, including one by Dulauroy et al. 2 in this issue of Nature Medicine, may draw the attention of The elusive source of myofibroblasts: problem solved?
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Fibrosis is omnipresent and contributes to a substantial proportion of all natural deaths. A recent study (pages 1262-1270) provides evidence that the mysterious perivascular cell, also known as the pericyte, is the cell type responsible for fibrotic disease in skin and skeletal muscle.
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